

SAPI CLINICAL TRIAL WORKING GROUP (CTWG) CHARTER

Key objectives / outcomes

The Clinical Trial Working Group (CTWG) is a sub-committee formed under SAPI Research & Development Committee (RDC) consisting of participants from SAPI member companies. The mandate of the CTWG is to support SAPI's vision of providing patients access to innovative treatments. We do this by helping to advance Clinical Research in Singapore. The CTWG will provide technical expertise and ground feedback in supporting the public and private sector in making Singapore an attractive and competitive location for local, regional and global clinical trials. Our vision is to make Singapore one of the best and most competitive locations to conduct clinical research.

Meeting Practices and Committee Rules

- Committee member companies may be competitors, creating the risk of anti-competitive conduct. The Committee will adopt the SAPI Competition Guidelines Governing Meetings in full as the rules by which the committee and its members will comply.
- The rules are designed to ensure that in organizing and attending meetings at which competing companies are present, the members avoid engaging in and facilitating any discussion or activity which might violate the competition laws of Singapore.
- The Committee Chair will remind participants of the Competition Guidelines on an annual basis, and with new members of the committee at the point of joining.
- A written agenda will be circulated in advance of each Committee meeting
- Discussion at the meeting should not generally deviate beyond the scope of the agenda
- Written minutes will be taken at the meeting and circulated to all participants after the meeting. The written minutes will also be stored by SAPI in line with its retention policy.
- Where there is doubt as to the legitimacy of a discussion, the Committee Chair, SAPI Secretariat and/ or any member participant must immediately stop the discussion and consider whether such discussion can be continued after SAPI has the opportunity to engage legal counsel to advise the legitimacy of such discussions.

Prohibited Conduct

It is unlawful to enter into agreements, whether binding or not, that significantly restrict competition in a market. In order to prevent agreements that lessen competition from occurring at meetings, members shall refrain from exchanging competitive information such as:

- Pricing strategies, product pricing, discounts, and credit terms
- Costs of production and distribution, output, methods of computing costs
- Specific suppliers and customers, including any discussion that may have the effect of excluding suppliers or customers from the market
- Confidential future plans of investment, marketing, and technological developments.